1. Home
  2. UCL vs CALC Comparison

UCL vs CALC Comparison

Compare UCL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$0.28

Market Cap

10.6M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$1.59

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
CALC
Founded
2014
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
19.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
UCL
CALC
Price
$0.28
$1.59
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $50.00
AVG Volume (30 Days)
★ 440.8K
60.0K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.99
N/A
P/E Ratio
$13.72
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.44
52 Week High
$2.63
$7.20

Technical Indicators

Market Signals
Indicator
UCL
CALC
Relative Strength Index (RSI) 26.84 43.09
Support Level N/A $0.51
Resistance Level $0.44 $2.31
Average True Range (ATR) 0.03 0.12
MACD 0.00 -0.09
Stochastic Oscillator 6.69 7.81

Price Performance

Historical Comparison
UCL
CALC

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: